Clinical trial

Prostate Cancer Biomarker Enrichment and Treatment Selection

NCT03385655

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-08-01

PhasePHASE2

Study timeline

Study start (actual)2018-08-01Date precision: day

Registry last updated2025-08-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

AdavosertibDRUG

SavolitinibDRUG

DarolutamideDRUG · verified · RxNorm: darolutamide

IpatasertibDRUG

Durvalumab and TremelimumabDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Canadian Cancer Trials Grouplead sponsor

Canadian Cancer Clinical Trials Networkcollaborator

BC Cancer Foundationcollaborator

Mapped research locations

MontrealQuebec, Canada2 TorontoOntario, Canada1 VancouverBritish Columbia, Canada1 OttawaOntario, Canada1 EdmontonAlberta, Canada1 LondonOntario, Canada1 HamiltonOntario, Canada1 HalifaxNova Scotia, Canada1 SaskatoonSaskatchewan, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03385655 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.